1. Home
  2. DHC vs MLYS Comparison

DHC vs MLYS Comparison

Compare DHC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diversified Healthcare Trust of Beneficial Interest

DHC

Diversified Healthcare Trust of Beneficial Interest

HOLD

Current Price

$4.70

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$36.99

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DHC
MLYS
Founded
1998
2019
Country
United States
United States
Employees
585
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
DHC
MLYS
Price
$4.70
$36.99
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$5.25
$46.40
AVG Volume (30 Days)
837.0K
1.7M
Earning Date
11-03-2025
11-10-2025
Dividend Yield
0.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,537,901,000.00
N/A
Revenue This Year
$4.79
N/A
Revenue Next Year
$3.32
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.10
N/A
52 Week Low
$2.00
$8.24
52 Week High
$4.99
$47.65

Technical Indicators

Market Signals
Indicator
DHC
MLYS
Relative Strength Index (RSI) 53.21 40.09
Support Level $4.65 $35.77
Resistance Level $4.99 $44.13
Average True Range (ATR) 0.14 1.93
MACD -0.02 -0.64
Stochastic Oscillator 44.33 14.95

Price Performance

Historical Comparison
DHC
MLYS

About DHC Diversified Healthcare Trust of Beneficial Interest

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs. Majority of revenue is from SHOP segment.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: